English
Bulgarian
Chinese (Simplified)
Croatian
Czech
Danish
Dutch
Finnish
French
German
Greek
Hebrew
Hindi
Indonesian
Italian
Japanese
Korean
Macedonian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swedish
Thai
Turkish
Vietnamese
CML Publications 2016
| Clinical Publications | Scientific Publications |
| December 2016 | |
| Response to overexpresssion of ABCB1 as prediction marker for CML: How close we are to translation into clinics? (Eadie LN et al. Leukemia, December 2016) (epub ahead of print) |
CYP2C8 genotype significantly alters imatinib metabolism in chronic myeloid leukemia patients (Barrat DT et al. Clin Pharmacokinet, December 2016) (epub ahead of print) |
| Cardiologist's perspective to the European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukemia (Constance C. et al. Leukemia, December 2016) (epub ahead of print) |
RT-q PCR and RT-Digital PCR: A comparison of different platforms for the evaluation of residual diseease in chronic myeloid leukemia Alikian M et al. Clin Chem, December 2016 (epub ahead of print) |
|
Chronic myeloid leukemia: sequencing of TKI therapies |
Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study (Rousselot P et al. Cancer, December 2016) (epub ahead of print) |
|
Molecular monitoring in chronic myeloid leukemia - how low can you go? |
Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients (Arun AK et al. Int J Lab Hematol, December 2016) (epub ahead of print) |
| Long-term bosutinib for chronic phase myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib (Cortes JE et al. Am J Hematol, December 2016) |
Enhanced targeting of CML stem and progenitor cells by inhibition of porcupine acyltransferase in combination with TKI (Agarwal P et al. Blood, December 2016) (epub ahead of print) |
| The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors (Efficace F et al. Hematology Am Soc Hematol Educ Program, December 2016) |
Response to overexpresssion of ABCB1 as prediction marker for CML: How close we are to translation into clinics? |
|
Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia |
|
|
Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy |
|
| November 2016 | |
|
How can I treat atypical CML? |
Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both BCR/Abl-dependent and BCR/Abl-independent mechanisms (Lan X et al. J Hematol Oncol, November 2016) |
| Second line small molecule therapy options for treating chronic myeloid leukemia (Molica M et al. Expert Opin Pharmacotherapy, November 2016) |
Cyclic AMO (cAMP) confers drug resistance against DNA damaging agents via PKAIA in CML cells (Xiao LY et al. Eur J Pharmacol, November 2016) (epub ahead of print) |
| Clinical efficacy of fecal occult blood test and colonoscopy for dasatinib-induced hemorrhagic colitis in CML patients (Nishiwaki S. et al. Blood, November 2016) (epub ahead of print) |
Upreguating miR-146a by pyscion reverses multidrug resistance in human chronic myelogenous leukemia K562/ADM cells (Liu W et al. Am J Cancer Res, November 2016) |
| Standardization of molecular monitoring for chronic myeloid leukemia in Latin America using locally produced secondary cellular calibrators (Ruiz MS et al. Leukemia, November 2016) |
Axl blockade by BGB324 inhibits BCR-ABL tyrosine kinase inhibitor-sensitive and -resistant chronic myeloid leukemia (Ben Batalla et al. Clin Cancer Res, November 2016) (epub ahead of print) |
| How can patient reported outcomes improve patient management in chronic myeloid leukemia? (De Marchi F. et al. Expert Rev Hematol, November 2016) (epub ahead of print) |
Different BCR/ABL protein suppression patterns as a converging trait of chronic myeloid leukemia cell adaptation to energy restriction |
| Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: A systematic review and meta-analysis (Haguet H et al. Expert Opin Drug Saf, November 2016) (epub ahead of print) |
Casiopeina III-Ea, a copper-containing small molecule, inhibits the in viro growth of primitive hematopoietic cells from chronic myeloid leukemia |
| Charlson comorbidity index predicts poor outcome in CML patients treated with tyrosine kinase inhibitor (Uemura M et al. Int J Hematol, November 2016) (epub ahead of print) |
IncRNA UCA1 contributes to imatinib resistance by acting as a ceRNA against miR-16 in chronic myeloid leukemia cells (Xiao Y et al. DNA Cell Biol, November 2016) (epub ahead of print) |
|
A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase
|
Gas6/AXL signaling regulates self-renewal of chronic myelogenous leukemia stem cells by stabilizing ß-catenin
|
| Celecoxib inhibits proliferation and survival of chronic myelogenous leukemia cells via AMPK-dependent regulation of ß-catenin and mTORC 1/2 (Riva B et al. Oncotarget, November 2016) (epub ahead of print) |
|
| Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenetic stimuli (Söderlund S. et al. Leuk Res, Nov, 2016) |
|
| The Rho-ROCK pathway is a new pathological mechanism of innate immune subversion in chronic myeloid leukaemia (Basbous S et al. J Pathol, November 2016) |
|
| Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL1 (35INS) (Berman E et al. Leuk Res, Oct 2016) |
|
| October 2016 | |
|
A population-based study of chronic myeloid leukemia patients treated with imatinib in first-line
|
PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia (Gupta P et al. Cancer Lett, October 2016) (epub ahead of print) |
| Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? (Rosti G. et al. Nat Rev Clin Oncol, October 2016) (epub ahead of print) |
CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression (Tarafdar A. et al. Blood, October 2016) (epub ahead of print) |
| Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship (Koller PB et al. Cancer, October 2016) (epub ahead of print) |
miRNAs in chronic myeloid leukemia: small molecules, essential function (Litwínska Z. et al. Leuk Lymphoma, October 2016) |
|
Current developments in molecular monitoring in chronic myeloid leukemia |
Programmed cell death 4 and BCR-ABL fusion gene expression are negatively correlated in chronic myeloid leukemia (Zhang X et al. Oncol Lett, Oct 2016) |
| September 2016 | |
|
Monitoring and defining early response: Where to draw the line? |
Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition (Scott MT et al. Cancer Discov, Sept 2016) (epub ahead of print) |
|
Discontinuation of TKI therapy and 'functional' cure for CML |
Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor treated CML stem cells (Zhang B et al. Blood, Sept 2016) (epub ahead of print) |
| Management of CML blast crisis (Hehlmann R. et al. Best Pract Res Clin Haematol, September 2016) |
Constitutional t(8;22) (q24;q11.2) that mimics the variant Burkitt-type translocation in Philadelphia chromosomal positiv chronic myeloid leukemia |
| Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidates to ponatinib: an expert opinion (Breccia M et al. Ann Hematol, Sept 2016) (epub ahead of print) |
Micro RNA-139-5p regulates proliferation of hematopoietic progenitors and is repressed during BCR-ABL mediated leukemogenesis (Choi J et al. Blood, Sept. 2016) (epub ahead of print) |
|
Dasatinib in imatinib-resistant or-intolerant chronic-phase chronic myeloid leukemia: 7-year follow-up of study CA180-034 |
Molecular monitoring of chronic myeloid leukemia: present and future
|
|
Ponatinib in the therapy of chronic myeloid leukemia |
Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells (Carter BZ et al. Sci Transl Med, September 2016) |
| August 2016 | |
|
Long-term bosutinib for chronic phase myeloid leukemia after failure of imatinib plus dasatinib and/or bosutinib (epub ahead of print)
|
The BCR-ABL/NF-kB signal transduction network: a long lasting relationship in Philadelphia positiv leukemias
|
| Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome (Iurlo A et al. Oncotarget, August 2016) (epub ahead of print) |
Cepheid xpert monitor platform for the confirmation of BCR-ABL1 is conversion factors for the molecular monitoring of chronic myeloid leukemia |
| Charlson comorbidity index predicts poor outcome in CML patients treated with tyrosine kinase inhibitor (Uemura M et al. Int J Hematol, August 2016) (epub ahead of print) |
ABCB1 overexpression is a key inhibitor of resistance to tyrosine kinase inhibitors in CML cell lines (Eadie LN et al. PLoS one, August 2016) |
| In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants. (Soverini S et al. BMC Cancer, August 2016) |
MiR-124-3p/B4GALT1 axis plays an important role in SOCS3-regulated growth and chemo-sensitivity of CML (Liu YX et al. J Hematol Oncol, August 2016) |
| Multiparameter analysis of off-target effects of dasatinib on bone homeostasis in patients with newly diagnosed myelogenous leukemia (Hoehn D. et al. Clin Lymphoma Myeloma Leuk, Aug 2016) |
miR-101 sensitized K562 cell line to imatinib through JAK2 downregulation and inhibition of NF-kB target genes (Farhadi E et al. Tumour Biol, August 2016) (epub ahead of print) |
| A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase (Takahashi K et al. Cancer, Aug 2016) |
|
| When to consider allogeneic transplantation in CML (Radich J, Clin Lymphoma Myeloma Leuk, Aug 2016) |
|
| Imatinib intolerance is associated with blastic phase development in Philadelphia chromosome-positive chronic myeloid leukemia (Ángeles-Velázquez JL. Clin Lymphoma Myeloma Leuk, August 2016) |
|
| July 2016 | |
| Summary of the published Indian data on chronic myeloid leukemia (Singhal MK et al. South Asian J Cancer, Jul-Sept, 2016) |
A role for FOX01 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia (Wagle M et al. Leukemia, July 2016) |
| Pattern of chronic myeloid leukemia in the imatinib era in a sub-Saharan African setting (Faye BF et al. Ann Hematol, July 2016) (epub ahead of print) |
TP53 codon 72 polymorphism predicts chronic myeloid leukemia susceptibility and treatment outcome (Weich N et al. Blood Celles Mol Dis, July 2016) |
|
A safety evaluation of omacetacine mepesuccinate for the treatment of chronic myeloid leukemia
|
Cooperation of imipramine and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia (Jorgensen KM et al. Oncotarget, July 2016) (epub ahead of print) |
| Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients (Dorer DJ et al. Leuk Res, July 2016) |
What are the challenges in 2016 regarding resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and cancer? (Lewis M et al. Hematol Oncol, July 2016) (epub ahead of print) |
| Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia (Castagnetti F. et al. Haematologica, July 2016) (epub ahead of print) |
Loss of mutL homolog-1 (MLH1) expression promotes acquisition of oncogenic and inhibitor-resistant points mutations in tyrosine kinases (Springuel L. et al. Cell Mol Life Sci, July 2016) (epub ahead of print) |
| Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies (Efficace F. et al. Support Care Cancer, July 2016) (epub ahead of print) |
Influence of CYP3A5*3 and ABCD1 C3435T on clinical outcomes and through plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia (Adeagbo BA et al. J Clin Pharm Ther, July 2016) (epub ahead of print) |
| Changes from imatinib mesylate to second generation tyrosine kinase inhibitors to improve renal impairment with imatinib mesylate in chronic myelogenous leukemia (Hino A et al. Int J Hematol, July 2016) (epub ahead of print) |
The clinical significance of ABCB1 overexpression in predicting outcome of patients undergoing first-line imatinib treatment (Eadie LN et al. Leukemia, July 2016) (epub ahead of print) |
| Advanced phase chronic myeloid leukemia in the TKI era - a report from the Swedish CML register (Söderlund S et al. Eur J Haematol, July 2016) (epub ahead of print) |
Measurement of BCR-ABL1 transcripts on the international scale in the United States: current status and best practices (Arora R et al. Leuk Lymphoma, July 2016) (epub ahead of print) |
| Pregnancy: part of life in chronic myelogenous leukemia (Law AD et al. Leuk Lymphoma, July 2016) (epub ahead of print) |
Impact of ABCD1 1236C> T-2677G> T-3435C> polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib
|
| Deep molecular reponses for treatment-free remission in chronic myeloid leukemia (Dulucq S et al. Cancer Med, July 2016) (epub ahead of print) |
The role for FOX01 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia (Wagle M et al. Leukemia, July 2016) |
| June 2016 | |
|
Incidence of second malignancies of chronic myelid leukemia during treatment with tyrosine kinase inhibitors |
Next-generation sequencing identifies major DNA methylation changes during progression of PH+ chronic myeloid leukemia |
| Discontinuing tyrosine kinase inhibitor therapy in chronic mylogenous leukemia: current understanding and future directions (Bhalla S. et al. Clin Lymphoma Myeloma Leuk, June 2016) (epub ahead of print) |
Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the international scale |
|
Management of pregnant chronic myeloid leukemia patients |
A novel tubulin polymerization inhibitor, MPT0B206, downregulates BCR-ABL expression and induces apoptosis in imatinib-sensitive and imatinib-resistant CML cells |
|
'Real-life' study of imatinib therapy in chronic-phase myeloid leukemia: A novel retrospective observational longitudinal analysis |
Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for chronic myeloid leukemia (CML) |
| Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population (Bower H et al. J Clin Onol, June 2016) (epub ahead of print) |
Drug repurposing for chronic myeloid leukemia: in silicio and in vitro investigation of DrugBank database for allosteric BCR-ABL inhibitors (Singh VK et al. J Biomol Struct Dyn, June 2016) (epub ahead of print) |
| Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML study IV (Miranda et al. Leukemia, June 2016) |
A novel BCR-ABL1 fusion gene identified by next-generation sequencing in chronic myeloid leukemia (Lyn X et al. Mol Cytogenet, June 2016) |
| Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: A population-based cohort study (Dahlén T et al. Ann Intern Med, June 2016) (epub ahead of print) |
MEF2C and CEBPA: Possible co-regulators in chronic myeloid leukemia disease progression (Agatheeswaran S. et al. Int J Biochem Cell Biol, June 2016) (epub ahead of print) |
|
Discontinuing tyrosine kinase inhibitor therapy in chronic mylogenous leukemia: current understanding and future directions |
Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells |
|
Incidence of second malignancies of chronic myelid leukemia during treatment with tyrosine kinase inhibitors (Yin XF et al. Clin Lymphoma Myeloma Leuk, June 2016) (epub ahead of print) |
High IL-7-levels in the bone marrow microenvironment mediate imatinib resistance and predict disease progression in chronic myeloid leukemia |
|
European LeukemiaNet recommendations for the managment and avoidance of adverse events of treatment in chronic myeloid leukemia
|
Unleashing the guardian: the targetable BCR-ABL/HAUSP/PML/PTEN network in CML (Morotti A et al. Curr Drug Targets, June 2016) (epub ahead of print) |
| Next-generation sequencing identifies major DNA methylation changes during progression of PH+ chronic myeloid leukemia (Heller G et al. Leukemia, June 2016) |
|
| Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the international scale (Cross NC et al. Leukemia, June 2016) (epub ahead of print) |
|
| Drug repurposing for chronic myeloid leukemia: in silicio and in vitro investigation of DrugBank database for allosteric BCR-ABL inhibitors (Singh VK et al. J Biomol Struct Dyn, June 2016) (epub ahead of print) |
|
| A novel BCR-ABL1 fusion gene identified by next-generation sequencing in chronic myeloid leukemia (Lyn X et al. Mol Cytogenet, June 2016) |
|
| A novel tubulin polymerization inhibitor, MPT0B206, downregulates BCR-ABL expression and induces apoptosis in imatinib-sensitive and imatinib-resistant CML cells (Chen CW et al. Apoptosis, June 2016) (epub ahed of print) |
|
| MEF2C and CEBPA: Possible co-regulators in chronic myeloid leukemia disease progression (Agatheeswaran S. et al. Int J Biochem Cell Biol, June 2016) (epub ahead of print) |
|
| Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for chronic myeloid leukemia (CML) (Liu F et al. Oncotarget, June 2016) (epub ahead of print) |
|
| May 2016 | |
|
Optimizing the use of TKI's in the management of chronic myelogenous leukemia |
Validation of a rapid one-step high sensitivity real-time quantitative PCR system for detecting major BCR-ABL1 mRNA on an international scale |
|
Setting global standards for stem cell research and clinical translation: The 2016 ISSCR guidelines |
ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome positive cells |
|
Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA 180-034 |
The non-genomic loss of function of tumor suppressors: an essential role in the pathogenesis of chronic myeloid leukemia chronic phase |
|
The treatment of CML at an environment with limited resources |
Next generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia |
| Final 5-year study results of DASASION: The dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial (Cortes JE et al. J Clin Oncol, May 2016) (epub ahead of print) |
The rs61764370 functional variant in the KRAS oncogene is associated with chronic myeloid leukemia risk in women (Gutiérrez-Malacatt H. et al. Asian Pac J Cancer Prev, 2016) |
| Frontline therapy with high-dose imatinib vs. 2nd generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis (Sasaki K et al. Haematologica, May 2016) (epub ahead of print) |
Effect of tyrosine kinase inhibitors of stemness in normal and chronic myeloid leukemia cells (Charaf L et al. Leukemia, May 2016) (epub ahead of print) |
| Management of advanced-phase chronic myelogenous leukemia (Radich JP. J Natl. Compr Canc Netw, May 2016) |
Comparison of branded and generics imatinib plasma concentrations in patients with chronic myelogenous leukemia - unicentric study (Ostojic A. et al. Clin Lymphoma Myeloma Leuk, May2016) |
|
Chronic myeloid leukemia reminiscences and dreams |
Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia (Irvine DA et al. Sci Rep, May2016) |
|
Safety and efficacy of the combination of pegylated interferon-alpha2b and dasatinib in newly diagnosed chronic phase chronic myeloid leukemia patients |
|
| Health-related quality of life outcomes in chronic myleloid leukemia patients treated with second generation tyrosine kinase inhibitors: Do we know enough? (Breccia M et al. Curr Med Res Opin, May 2016) |
|
| April 2016 | |
| Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial (Lipton JH et al. Lancet Oncol, April 2016) (epub ahead of print) |
Identification of CD25 as STAT5 dependent growth regulator of leukemic stem cells in PH+ CML |
| Molecular monitoring of tyrosine kinase inhibitor therapy of chronic myeloid leukemia in China (Jiang Q et al. J Cancer Res Clin Oncol, April 2016) (epub ahead of print) |
Early BCR-ABL reduction is predictive of better event-free survival in patients with newly diagnosed chronic myeloid leukemia treated with any tyrosine kinase inhibitor |
| Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure (Whitely J et al. Curr Med Res Opin, April 2016) (epub ahead of print) |
Modeling BCR-ABL and MLL-AF9 leukemia in a human bone marrow-like scaffold based xenograft model |
| Monitoring disease burden in chronic myeloid leukemia: past, present, and future (Egan D. et al. Am J Hematol, April 2016) (epub ahead of print) |
Quantitative analysis of mutant subclones in chronic myeloid leukemia: comparison of different methodological approaches (Preuner S. et al. Int J Mol Sci, April) |
|
|
Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects Culen M et al. Oncotarget, April 2016 (epub ahead of print) |
|
|
Mtss1 is a critical epigenetically regulated tumor suppressor in CML |
|
The impact of multiple low-level BCR-ABL1 mutations on response to Ponatinib |
|
| Combined population dynamics and entropy modelling supports patients stratification in chronic myeloid leukemia (Brehme M et al. Sci Rep, April 2016) |
|
| March 2016 | |
| Cross-intolerance with dasatinib among imatinib-intolerant patients with chronic phase myeloid leukemia
(Khoury HJ et al. Clin Lymphoma Myeloma Leuk, March 2016) |
Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy (Wang W et al. Blood, March 2016) (epub ahead of print) |
| Hyperhomocysteinemia and high doses of nilotinib favor cardiovascular events in chronic phae chronic myelogenous leukemia patients (Fossard G. et al. Haematologica, March 2016) |
Leukemic stem cell quantification in newly diagnosed chronic myeloid leukamia patients predict response to nilotinib therapy (Thielen N et al. Clin Cancer Res, March 2016) (epub ahead of print) |
|
Increased prevalance of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia |
A role for FOXO1 in BCR-ABL-1 independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia |
| Next generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients (Soverini S. et al. Oncotarget, March 2016) (epub ahead of print) |
The role of Fas-associatd phosphotase 1 in leukemia stem cell persistence during tyrosine kinase inhibitor treatment of chronic myeloid leukemia (Huang W et al. Leukemia, March 2016) (epub ahead of print) |
|
Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity |
Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway (Chen JR et al. Int. J Oncol, March 2016) (epub ahead of print) |
|
Long-term evaluation of cardiac and vascular toxicity in patients with philadelphia chromosome positive leukemias treated with Bosutinib |
Characteristics of BCR-ABL kinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance |
|
Splenic irradication before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study |
Micro RNAs mediated regulation of MAPK signaling pathways in chronic myeloid leukemia |
|
Rotation of nilotinib and imatinib for first-line treatment of chronic myeloid leukemia |
Overexpression of RPS27a contributes to enhanced chemoresistance of CML cells to imatinib by the transactivated STAT3 (Wang H et al. Oncotarget, March 2016) (epub ahead of print) |
| Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States (Padula WV et al. J Natl Cancer Inst., March 2016) (epub ahead of print) |
NUMB inactivation confers resistance to imatinib in chronic myeloid leukemia cells (Garcia-Alegría E et al. Cancer Lett, March 2016) (epub ahead of print) |
|
New methodologies in the molecular monitoring of CML |
c-MYB is a transcriptional regulator of ESPL1/separase in BCR-ABL-positive chronic myeloid leukemia (Prinzhorn W et al. Biomark Res, March 2016) (epub ahead of print) |
|
Clinical safety and efficacy of nilotinib or dasatinib in patients with newly diagnosed chronic-phase chronic myelogenous leukemia and pre-existing liver and/or renal dysfunction |
Next generation sequencing-assisted DNA-based digital PCR for a personalized approach to the detection and quantification of residual disease in chronic myeloid leukemia patients |
| Present and future of molecular monitoring in chronic myloid leukaemia (Soverini S et al. Br J Haematol, March 2016) (epub ahead of print) |
Next generation sequencing-assisted DNA-based digital PCR for a personalized approach to the detection and quantification of residual disease in chronic myeloid leukemia patients (Alikian M et al. J Mol Diagn, March 2016) |
| Is cure for chronic myeloid leukemia possible in the tyrosine kinase inhibitors era? (Bansal A et al. Curr Opin Hematol, March 2016) (epub ahead of print) |
|
|
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial |
|
| February 2016 | |
| Evaluating the impact of a switch to nilotinib on imatinib-related chronic low-grade adverse events in patients with CML-CP: The ENRICH study (Cortes JE et al. Clin Lymphoma Myeloma Leuk, February 2016) (epub ahead of print) |
High CIP2A levels correlates with an antiapoptoic phenotype that can be overcome by targeting BCL-XL in chronic meyloid leukemia (Lucas CM et al. Leukemia, February 2016) (epub ahead of print) |
| Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia (Caldemeyer L et al. Curr Hematol Malig Rep, February 2016) (epub ahead of print) |
Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib resistance preventing rpS6 phosphorylation in chronic meyloid leukaemia cells: new combined therapeutic strategies |
| Hematologic malignancies in pregnancy: Management guidelines from an international consensus (Lishner M et al. J Clin Oncol, February 2016) |
BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukemia (Latham S et al. J Clin Pathol, February 2016) (epub ahead of print) |
|
Quality of life and long-term therapy in patients with chronic myeloid leukemia |
Hsp90 inhibitor, BIIBo21, induces apoptosis and authopagy by regulating mTOR-UIIK1 pathway in imatinib-sensitive and-resistant chronic myeloid leukemic cells (He W et al. Int J Oncol, February 2016) |
|
Omacetaxine Mepesuccinate for chronic myeloid leukemia |
Normal ABL1 is a tumour suppressor and therapeutic target in human and mouse leukemias expressing oncogeneic ABL1 kinase (Dasgupta Y et al. Blood, February 2016) |
| Analysis of 2013 European LeukemiaNET (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcome (Jain P et al. Br. J Hematol, February 2016) |
Heterogeneity of leukemia-initiating capacity of chronic meylogenous leukemic stem cells (Zhang B et al. J Clin Invest, February 2016) (epub ahead of print) |
| Chronic Myeloid Leukemia: 2016 update on diagnosis, therapy and monitoring (Jabbour E et al. Am J Hematol, February 2016) |
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients (Deiniger MW et al. Blood, February 2015) |
| Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response and overall survival: A systemic review and meta-analysis (Douxfils J et al. JAMA Oncol, February 2016) (epub ahead of print) |
The role of microRNAs in the pathogenesis and drug resistance of chronic myelogenous leukemia (Review (Di Stefano C et al. Oncol Rep, February 2016) |
| The reality of cancer treatment in a developing country: the effects of delayed TKI treatment on survival, cytogenetic and molecular responses in chronic myeloid leukaemia patients (Kurtovic-Kozaric A et al. Br J Haematol, February 2016) (epub ahead of print) |
|
| Allogeneic transplantation for CML in the TKI era: striking the right balance (Innes AJ et al. Nat Rev Clin Oncol, February 2016) |
|
| January 2016 | |
| Conditional survival with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors (Sasaki K et al. Cancer, January 2016) |
The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib (Parker WT et al. Blood, January 2016) (epub ahead of print) |
| Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France intergroup des leucémies myéloides chroniques (Rea D et al. Bull Cancer, January 2016) |
Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia (Tanrikulu Simsek E et al. J Clin Pathol, January 2016) |
| Dasatinib first-line: Multicentric Italian experience outside clinical trials (Breccia M et al. Leuk Res, January 2016) |
Impact of BCR-ABL transcript type on response and survival in patients with chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors (epub ahead of print) |
| Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia (Pfirrmann M et al. Leukemia, January 2016) |
Identification and characterization of tyrosine kinase nonreceptor 2 mutations in leukemia through integration of kinase inhibitor screening and genomic analysis |
| Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase myeloid leukaemia resistant or intolerant to imatinib (Brümmendorf TH et al. Br J Haematol, January 2016) (epub ahead of print) |
In silico identifcation of inhibitors against mutated BCR-ABL protein screening and molecular dynamics simultation study (Kumar H et al. J Biomol Struct Dyn, January 2016) (epub ahead of print) |
| Conditioned survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors (Sasaki K et al. Cancer, January 2015) |
|
| Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase (Akard LP et al. Leuk Lymphoma, January 2016) (epub ahead of print) |
|
Would you like to suggest an interesting paper or article? >> Please provide us with the details here and we will be happy to review your suggestion!
Search for more publications on CML at PubMed.gov
